Log in with your email address username.


[Comment] Multimodal treatment of non-small-cell lung cancer

In The Lancet, Miklos Pless and colleagues1 report a prospective randomised trial of induction chemotherapy followed by accelerated radiotherapy and surgery, compared with induction chemotherapy followed by surgery, to treat patients with stage IIIA/N2 non-small-cell lung cancer. 232 patients were enrolled in 23 study centres and were randomly assigned to the study groups in a 1:1 ratio. Median event-free survival, the trial’s primary endpoint, was similar in the two groups (12·8 months, 95% CI 9·7–22·9 in the chemoradiotherapy group and 11·6 months, 8·4–15·2 in the chemotherapy group), as was overall survival (37·1 months [22·6–50·0] and 26·2 months, 19·9–52·1, respectively).